Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Devlin, Kathryn
AVALON, NCT05243524 / 2022-003666-20: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer	Terminated	2b	16	Canada, US	Maveropepimut-S, MVP-S, DPX-Survivac, Cyclophosphamide 50mg, CPA, Procytox, Cytoxan	ImmunoVaccine Technologies, Inc. (IMV Inc.), Immunovaccine Technologies Inc. (IMV Inc.)	Platinum-resistant Epithelial Ovarian Cancer	07/23	08/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Devlin, Kathryn
AVALON, NCT05243524 / 2022-003666-20: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer	Terminated	2b	16	Canada, US	Maveropepimut-S, MVP-S, DPX-Survivac, Cyclophosphamide 50mg, CPA, Procytox, Cytoxan	ImmunoVaccine Technologies, Inc. (IMV Inc.), Immunovaccine Technologies Inc. (IMV Inc.)	Platinum-resistant Epithelial Ovarian Cancer	07/23	08/23